Veru Inc (VERU)

NASDAQ
5.470
-0.360(-6.17%)
After Hours
5.470
0.000(0.00%)
- Real-time Data
  • Volume:
    3,055,046
  • Day's Range:
    5.405 - 5.830
  • 52 wk Range:
    4.340 - 24.550

VERU Overview

Prev. Close
5.83
Day's Range
5.405-5.83
Revenue
39.35M
Open
5.79
52 wk Range
4.34-24.55
EPS
-1.05
Volume
3,055,046
Market Cap
441.01M
Dividend (Yield)
N/A
(N/A)
Average Volume (3m)
4,997,086
P/E Ratio
-5.30
Beta
-0.331
1-Year Change
-13.63%
Shares Outstanding
80,623,128
Next Earnings Date
Feb 07, 2023
What is your sentiment on Veru?
or
Market is currently closed. Voting is open during market hours.

Veru Inc News

Veru Inc Analysis

Veru Inc Company Profile

Veru Inc Company Profile

Employees
252

Veru Inc., a biopharmaceutical company, focuses on developing medicines for the management of COVID-19, and breast and prostate cancers. Its commercial products comprise FC2 female condom/internal condom for the protection against unintended pregnancy and the transmission of sexually transmitted infections; and Entadfi, a capsule for the treatment of urinary tract symptoms. The company’s drug candidates under development include Enobosarm, an oral selective androgen receptor agonist that is in phase III clinical trial for the treatment of AR+ ER+ HER2- metastatic breast cancer; Sabizabulin, which is phase 2b clinical trial for the treatment of AR+ ER+ HER2- metastatic breast cancer; and Enobosarm + abemaciclib combination therapy, which is in phase III clinical trial for the treatment of AR+ ER+ HER2- metastatic breast cancer. In addition, its drug candidate also comprise Sabizabulin, which is in Phase 3 clinical trial for the treatment of metastatic castration and androgen receptor targeting agent resistant prostate cancer; VERU-100, a GnRH antagonist peptide injection, which is in Phase II clinical trial for the treatment of advanced hormone sensitive prostate cancer; Zuclomiphene Citrate, which is in Phase 2b clinical trial for treating hot flashes; and Sabizabulin, an oral microtubule disruptor with dual antiviral and anti-inflammatory to severe COVID-19 patients at risk for acute respiratory distress syndrome. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was incorporated in 1971 and is headquartered in Miami, Florida.

Read More

Analyst Price Target

Average18.800 (+243.693% Upside)
High31.000
Low3.000
Price5.470
No. of Analysts4
Strong Sell
Sell
Neutral
Buy
Strong Buy
Buy
Analysts 12-Month Price Target

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesSellSellStrong SellStrong SellSell
Technical IndicatorsSellStrong SellStrong SellStrong SellStrong Sell
SummarySellStrong SellStrong SellStrong SellStrong Sell